Comparative Pharmacology
Head-to-head clinical analysis: CARBAMAZEPINE versus CARBATROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBAMAZEPINE versus CARBATROL.
CARBAMAZEPINE vs CARBATROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbamazepine stabilizes the inactivated state of voltage-gated sodium channels, thereby reducing neuronal excitability and repetitive firing. It also potentiates GABAergic transmission and affects calcium and potassium channels.
Stabilizes neuronal membranes by blocking voltage-gated sodium channels, inhibiting repetitive firing of action potentials. Also enhances GABAergic activity.
Initial 200 mg orally twice daily, increase by 200 mg/day every 7 days; usual maintenance 800-1200 mg/day in divided doses (max 1600 mg/day).
Initial dose 200 mg orally twice daily, increase by 200 mg/day at weekly intervals; maintenance 800-1200 mg/day in 2 divided doses extended-release capsules.
None Documented
None Documented
Clinical Note
moderateCarbamazepine + Digoxin
"The metabolism of Digoxin can be increased when combined with Carbamazepine."
Clinical Note
moderateCarbamazepine + Digitoxin
"The metabolism of Digitoxin can be increased when combined with Carbamazepine."
Clinical Note
moderateCarbamazepine + Torasemide
"The metabolism of Torasemide can be increased when combined with Carbamazepine."
Clinical Note
moderateCarbamazepine + Clobetasol propionate
Initial: 25-65 hours (single dose), then 12-17 hours (chronic dosing due to autoinduction). Clinical context: autoinduction reduces half-life over 3-5 weeks; adjust dosing accordingly.
Terminal elimination half-life 25-65 hours initially, then 12-17 hours after autoinduction; clinical context: requires dose adjustment after 3-5 weeks.
Renal: 72% (primarily as metabolites including carbamazepine-10,11-epoxide, with ~1-3% as unchanged drug); Fecal: 28% via biliary elimination.
Renal: 70% as metabolites (including carbamazepine-10,11-epoxide) and 2-3% as unchanged drug; biliary/fecal: 30%.
Category D/X
Category C
Anticonvulsant
Anticonvulsant
"The serum concentration of Clobetasol propionate can be decreased when it is combined with Carbamazepine."